The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

Despite the recent increase in the development of antivirals and antibiotics, antimicrobial
resistance and the lack of broad-spectrum virus-targeting drugs are still important issues and …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Abstract Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a
complicated challenge, especially among patients with severe disease. In recent studies …

Tofacitinib is the first Janus kinase (JAK) inhibitor commercially approved for the treatment of
rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently …

Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of
molecules associated with one of the major pathways through which many cytokines exert …

Background Final data are presented for the ORAL Sequel long-term extension (LTE) study
evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 …

Accumulating data on cellular and molecular pathways help to develop novel therapeutic
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …

Cytokines play a central role in the pathophysiology of autoimmune and inflammatory
diseases. Several cytokines signal through the JAK-STAT pathway, which is now recognized …

Objectives To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid
arthritis patients receiving JAK inhibitors. Methods We conducted a systematic literature …